Wgi Dm LLC Raises Stock Position in Icon Plc $ICLR

Wgi Dm LLC lifted its position in Icon Plc (NASDAQ:ICLR) by 9.2% during the 4th quarter, Holdings Channel reports. The firm owned 1,396,009 shares of the medical research company’s stock after acquiring an additional 118,029 shares during the period. Icon comprises about 19.0% of Wgi Dm LLC’s holdings, making the stock its 3rd biggest holding. Wgi Dm LLC’s holdings in Icon were worth $254,381,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in ICLR. WINTON GROUP Ltd bought a new position in shares of Icon in the second quarter worth approximately $254,000. Daiwa Securities Group Inc. grew its holdings in shares of Icon by 19.3% in the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock worth $4,094,000 after purchasing an additional 4,546 shares during the last quarter. Frontier Capital Management Co. LLC grew its holdings in shares of Icon by 97.6% in the second quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock worth $10,379,000 after purchasing an additional 35,253 shares during the last quarter. Peapack Gladstone Financial Corp bought a new position in shares of Icon in the second quarter worth approximately $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Icon by 58.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after purchasing an additional 289 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ICLR shares. Weiss Ratings cut shares of Icon from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 18th. Rothschild & Co Redburn set a $100.00 price target on shares of Icon and gave the company a “neutral” rating in a report on Tuesday, February 17th. Zacks Research cut shares of Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. Citigroup cut their price target on shares of Icon from $200.00 to $120.00 and set a “neutral” rating on the stock in a report on Wednesday, March 11th. Finally, Robert W. Baird set a $119.00 price target on shares of Icon in a report on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $149.38.

Icon Stock Performance

Shares of ICLR stock opened at $116.38 on Friday. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00. The stock has a market cap of $9.40 billion, a PE ratio of 15.75, a price-to-earnings-growth ratio of 3.04 and a beta of 1.23. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The company’s fifty day moving average price is $109.72 and its 200-day moving average price is $144.82.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.